PMID- 29321773
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 8
DP  - 2017
TI  - The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer 
      Immunotherapy.
PG  - 1718
LID - 10.3389/fimmu.2017.01718 [doi]
LID - 1718
AB  - T cells can recognize peptides encoded by mutated genes, but analysis of 
      tumor-infiltrating lymphocytes suggests that very few neoantigens spontaneously 
      elicit T-cell responses. This may be an important reason why immune checkpoint 
      inhibitors are mainly effective in tumors with a high mutational burden. Reasons 
      for clinically insufficient responses to neoantigens might be inefficient 
      priming, inhibition, or deletion of the cognate T cells. Responses can be 
      dramatically improved by cancer immunotherapy such as checkpoint inhibition, but 
      often with temporary effects. By contrast, T cells from human leukocyte antigen 
      (HLA)-matched donors can cure diseases such as chronic myeloid leukemia. The 
      therapeutic effect is mediated by donor T cells recognizing polymorphic peptides 
      for which the donor and patient are disparate, presented on self-HLA. Donor 
      T-cell repertoires are unbiased by the immunosuppressive environment of the 
      tumor. A recent study demonstrated that T cells from healthy individuals are able 
      to respond to neoantigens that are ignored by tumor-infiltrating T cells of 
      melanoma patients. In this review, we discuss possible reasons why neoantigens 
      escape host T cells and how these limitations may be overcome by utilization of 
      donor-derived T-cell repertoires to facilitate rational design of 
      neoantigen-targeted immunotherapy.
FAU - Karpanen, Terhi
AU  - Karpanen T
AD  - Department of Cancer Immunology, Institute for Cancer Research, Oslo University 
      Hospital Radiumhospitalet, and K.G. Jebsen Center for Cancer Immunotherapy, 
      University of Oslo, Oslo, Norway.
FAU - Olweus, Johanna
AU  - Olweus J
AD  - Department of Cancer Immunology, Institute for Cancer Research, Oslo University 
      Hospital Radiumhospitalet, and K.G. Jebsen Center for Cancer Immunotherapy, 
      University of Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171211
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5732232
OTO - NOTNLM
OT  - T cell
OT  - allogeneic hematopoietic stem cell transplantation
OT  - donor
OT  - donor lymphocyte infusion
OT  - graft versus tumor effect
OT  - immunotherapy
OT  - minor histocompatibility antigen
OT  - neoantigen
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:01
PMCR- 2017/01/01
CRDT- 2018/01/12 06:00
PHST- 2017/09/08 00:00 [received]
PHST- 2017/11/21 00:00 [accepted]
PHST- 2018/01/12 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2017.01718 [doi]
PST - epublish
SO  - Front Immunol. 2017 Dec 11;8:1718. doi: 10.3389/fimmu.2017.01718. eCollection 
      2017.